The 11 most recent market catalysts affecting $SRPT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 10, 2026
Corporate Catalyst
Bullish
Impact 55
Deutsche Bank Upgrades Sarepta Therapeutics to Hold
Deutsche Bank upgraded Sarepta Therapeutics from 'Sell' to 'Hold' and raised its price target from $14 to $18. This change reflects a more positive, or at least less negative, view…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 75
Sarepta Therapeutics Reports Third Quarter 2026 Financial Results
Sarepta Therapeutics released its third-quarter 2026 financial results, emphasizing a strong financial position and ongoing commitment to its Duchenne muscular dystrophy franchise …
Oct 14, 2026
Corporate Catalyst
Bullish
Impact 85
Sarepta Says SRP-1003 Cut Disease-Causing RNA In Cell Nucleus By Up To ~80% In Preclinical Myotonic Dystrophy Model
This preclinical data for SRP-1003 represents a significant positive catalyst for Sarepta Therapeutics. Reducing disease-causing RNA by up to 80% in a preclinical model suggests st…
Oct 8, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $17
RBC Capital analyst Brian Abrahams has lowered the price target for Sarepta Therapeutics (SRPT) from $19 to $17, while maintaining a 'Sector Perform' rating. This action suggests a…
Oct 5, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a 'Sell' rating on Sarepta Therapeutics (SRPT) and maintained a $5 price target. This action is significant because it…
Sep 30, 2026
Corporate Catalyst
Bearish
Impact 55
JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20
JP Morgan analyst Anupam Rama maintained a 'Neutral' rating on Sarepta Therapeutics (SRPT) but lowered the price target from $23 to $20. This action signals a slightly diminished v…
Sep 30, 2026
Corporate Catalyst
Bullish
Impact 75
Sarepta Therapeutics Presents New Data At 31st Annual Congress Of WMS That Provide Evidence Of Clinically Meaningful Functional Benefit Of ELEVIDYS In Older Ambulatory Patients With Duchenne Muscular Dystrophy
Sarepta Therapeutics announced new data from their ELEVIDYS drug, demonstrating clinically meaningful functional benefits in older ambulatory Duchenne muscular dystrophy patients (…
Jul 27, 2026
Corporate Catalyst
Neutral
Impact 75
Sarepta Therapeutics Appoints Michael Severino CEO, Effective July 28, Succeeding Doug Ingram
Sarepta Therapeutics has announced a significant leadership transition with the appointment of Michael Severino as CEO, effective July 28, 2026, replacing the retiring Doug Ingram.…
Jul 27, 2026
Corporate Catalyst
Neutral
Impact 95
FDA Staff Review Says Data For Co's Duchenne Cell Therapy Does Not Provide Substantial Evidence Of Effectiveness
The FDA staff review, released ahead of an advisory committee meeting, states that the data for the company's Duchenne cell therapy does not provide substantial evidence of effecti…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.